16 November 2026
Aptamer Group plc
("Aptamer", the "Company" or the "Group")
Board and Senior Leadership Changes
Aptamer Group plc (AIM: APTA), the developer of next-generation synthetic Optimer® binders, today announces changes to its Board and senior leadership team, effective immediately. These changes bring specialist expertise in oligonucleotide therapeutics and delivery, as the Group advances its own targeted therapeutic programmes, in line with the strategy set out by the Company in March 2026.
Dr Paloma Giangrande, a specialist in aptamer-mediated RNA delivery and a member of the Company’s Scientific Advisory Board, joins the Board as a Non-Executive Director.
Dr James McNamara is appointed Head of Oligonucleotide Therapeutic Development, reporting to the Chief Executive Officer, to lead the Group’s oligonucleotide therapeutic programmes.
Dr David Bunka has stepped down from the Board and remains with the Company as Head of Research and Development, reporting to the Chief Executive Officer.
Dr Adam Hargreaves, Chair of the Board, commented: "On behalf of the Board, I am delighted to welcome Paloma as a Non-Executive Director. She has taken RNA medicines from discovery into the clinic and has worked with our team through the Scientific Advisory Board since December 2024. Her experience will strengthen the Board's oversight of our therapeutic programmes, including the in vivo study in Optimer®-targeted radiotherapy led by Dr Louis Allott, Director of Radioligand Development, and the oligonucleotide delivery studies James will lead. I also thank David for his contribution as a Director since the Company's foundation and look forward to his continued contribution as Head of Research and Development."
Dr Arron Tolley, Chief Executive Officer, commented: "In March 2026 we set out a plan to build a proprietary therapeutic business on the Optimer® platform, alongside our fee-for-service discovery business, focused on undruggable targets and delivery beyond the liver. We are making strong progress against that plan. Our AI/ML build was completed six months early, automation is integrated, lead candidate generation for therapeutic applications has started, and our first in vivo study, in Optimer®-targeted radiotherapy, is underway.
"I have worked with Paloma for almost two years through the Scientific Advisory Board, and I am delighted to welcome her to the Board and James as Head of Oligonucleotide Therapeutic Development. Both Paloma and James helped pioneer aptamer-mediated siRNA delivery, and their expertise adds translational depth to our existing team as our programmes move into in vivo evaluation. We see a compelling opportunity to turn the strengths of the Optimer® platform into proprietary assets that address unmet needs and can attract pharmaceutical partners. Our focus is on generating the evidence to support that, and I look forward to updating shareholders as the data emerge."
Director Appointment
Dr Paloma Giangrande is an internationally recognised expert in nucleic acid therapeutics and delivery. At the University of Iowa, she pioneered the use of RNA aptamers for targeted siRNA delivery beyond the liver, expanding the therapeutic potential of RNA interference. Paloma has since held senior leadership roles at Moderna and Wave Life Sciences, where she took an RNA editing programme into first-in-human studies, and at Eleven Therapeutics, where she was Chief Technology Officer.
Most recently, she was Senior Vice President of Discovery and Translational Biology at Orbital Therapeutics, where she oversaw the discovery platform and preclinical and early clinical RNA immunotherapy programmes acquired by Bristol Myers Squibb in December 2025 for US$1.5 billion. Paloma has served on the Company's Scientific Advisory Board since December 2024 and will continue in that role upon joining the Board.
Dr Paloma Giangrande, Non-Executive Director, commented: "Having worked with the team through the Scientific Advisory Board and seen first-hand what the Optimer® platform can do, I am pleased to be joining the Board. Targeted delivery is the field I have spent my career in, and I believe Aptamer has the technology and the team to make real progress in it. I look forward to helping the Company deliver on that potential."
Appointment of Head of Oligonucleotide Therapeutic Development
In his new role, Dr James McNamara will lead the Group's oligonucleotide therapeutic programmes, including the in vivo studies funded in March 2026. He is a biotechnology executive and scientist specialising in aptamers, oligonucleotide chemistry, RNA therapeutics and molecular diagnostics. At Duke University, James and Paloma developed one of the first methods for using aptamers to deliver siRNA to specific cell types, the approach on which the Group’s targeted delivery programmes are built. He was Associate Professor of Internal Medicine at the University of Iowa and Founder and Chief Executive Officer of Nuclease Probe Technologies, Inc., which developed nucleic acid-based diagnostics for bacterial pathogens. James is married to Paloma Giangrande.
Director Resignation
Dr David Bunka co-founded the Company with Dr Arron Tolley in 2008 and has served as a Director since its foundation. David has stepped down from the Board and remains with the Company as Head of Research and Development. In this role, he leads the continuous improvement and development of the Group's automated Optimer® selection platforms. The high-throughput data these platforms generate underpin the Group's fee-for-service business, the generation of therapeutic lead candidates and the AI-enabled discovery engine. David has chosen to step down from the Board to concentrate fully on these areas, where he adds the most value.
Additional disclosures regarding Dr Giangrande’s appointment:
The following details in relation to the appointment of Dr Paloma Hoban Giangrande, aged 54, are disclosed in accordance with Schedule 2(g) of the AIM Rules:
|
Current directorships: |
Former appointments within the past 5 years: |
|
Program Therapeutics Inc |
American Society for Gene & Cell Therapy (ASGCT)" |
|
Biologic Insights LLC |
|
Dr Giangrande holds no ordinary shares in the Company. No further information is required to be disclosed under Schedule 2(g) of the AIM Rules for Companies.
- Ends -
For further information, please contact:
|
Aptamer Group plc Dr Arron Tolley |
+44 (0) 1904 217 404
|
|
SPARK Advisory Partners Limited - Nominated Adviser Andrew Emmott / Dillon Wall |
+44 (0) 20 3368 3550 |
|
Cavendish Capital Markets Limited – Joint Broker Geoff Nash / Seamus Fricker / Joe Smith |
+44 (0) 20 7220 0500 |
|
Turner Pope Investments (TPI) Limited – Joint Broker Andrew Thacker / Guy McDougall |
+44 (0) 20 3657 0050 |
|
Northstar Communications Limited - Investor Relations Sarah Hollins |
+44 (0) 113 730 3896 |
About Aptamer Group
Aptamer Group plc (AIM: APTA) develops Optimer® binders, next-generation synthetic alternatives to antibodies that offer high specificity, improved stability, lower cost and access to targets beyond the reach of conventional modalities.
The Group operates a dual-revenue model, generating near-term revenues through fee-for-service discovery programmes while building a portfolio of proprietary therapeutic assets designed to create long-term value through licensing, royalties and supply agreements.
Aptamer is strategically focused on two of the most significant challenges in modern drug development: targeting "undruggable" proteins and enabling delivery of therapeutics to tissues beyond the liver. Its proprietary Optimer® platform, supported by more than 15 years of discovery data and an expanding AI-enabled discovery engine, is designed to accelerate the identification of high-quality binders against challenging biological targets.
The Group's internal pipeline includes targeted delivery vehicles for oligonucleotide therapeutics and radioligand therapy programmes, with in vivo studies expected to support future partnering and licensing opportunities.
Founded in 2008 and headquartered in York, UK, Aptamer works with many of the world's leading pharmaceutical companies, combining platform expertise, proprietary data and therapeutic innovation to create shareholder value.